Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, October 23, 2019
Foamix has entered into a long term contract manufacturing and supply agreement with ASM for AMZEEQ™ topical foam, 4%.
read more
Fluxergy is making a $30 million investment to expand its capability to scale production of the Fluxergy Analyzer diagnostic testing system in response to the COVID-19 pandemic.
read more
The Russian pharmaceutical market is developing rapidly; it takes 11th place in the rating of pharmaceutical market volumes worldwide and is predicted to go up to 9th place by 2016. Along with its growing potential, important changes in the industry ...
read more
Friday, November 06, 2020
Flamma has entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury (remdesivir) supply chain.
read more
The Flamma Group, a company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) ...
read more
Friday, November 13, 2020
Flamma entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury supply chain.
read more
Flamma announced the ground breaking for their new R&D building.
read more
Thursday, September 08, 2022
Flagship Biosciences announced the acquisition of Interpace Pharma Solutions ("IPS"), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions.
read more
Wednesday, April 17, 2019
Fibrocell announced a collaboration agreement with Castle Creek to develop and commercialize FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
read more
According to the complaint, despite Delta Pharma’s repeated promises to correct deficiencies, Delta Pharma continued to violate the law.
read more
U.S. District Judge Kristine G. Baker for the Eastern District of Arkansas entered a consent decree of permanent injunction today between the U.S. and Cantrell Drug Company of Little Rock, Arkansas, and the company’s Chief Executive Officer and co-...
read more
Tuesday, October 23, 2018
A federal court ordered a Tennessee-based company to stop selling OTC drug products until the company complies with the Federal Food, Drug, and Cosmetic Act and other requirements listed in a consent decree.
read more
U.S. District Judge Robert J. Shelby entered a consent decree of permanent injunction between the U.S. and Isomeric Pharmacy Solutions, two of the company’s co-owners and COO.
read more
Thursday, February 07, 2019
The U.S. District Court for the Western District of Pennsylvania entered a consent decree of permanent injunction between the US and Ranier’s Rx Laboratory and owner/pharmacist Francis H. Ranier.
read more
Tuesday, December 20, 2022
The U.S. District Court for the Western District of Oklahoma entered a consent decree against Qualgen LLC, an outsourcing facility with a history of violations.
read more